This post was originally published on this site My daughter’s high school English class is reading a poem by Emily Dickinson. It begins with: “’Hope’ is the thing with feathers.” I read the poem in high school, too. I’ll be honest, even with all of the English courses I took, I never fully understood what…
This post was originally published on this site Tesaro (niraparib) and Lymparza (olaparib) — both PARP1 inhibitors approved by the U.S. Food and Drug Administration to treat breast and ovarian cancer patients — also kill malignant pleural mesothelioma (MPM) cells, a new in vitro study finds. The study, “Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition,”…
This post was originally published on this site Immune checkpoint inhibitor Keytruda (pembrolizumab) did not significantly improve the survival outcomes of previously treated hepatocellular carcinoma patients on best supportive care, results from a Phase 3 trial show. While a trend was seen toward extended survival and delayed disease progression or death, the results did not…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved an under-the-skin formulation of Genentech‘s breast cancer treatment Herceptin (trastuzumab), called Herceptin Hylecta. Also by Genentech, the treatment consists of a combination of trastumuzab and recombinant human hyaluronidase PH20, a protein that helps deliver the antibody under the skin. “Over the past…
This post was originally published on this site Genetic characterization and the detection of PD-1 ligand protein (PD-L1) levels in non-small cell lung cancers (NSCLC) can help oncologists identify those who may benefit the most from Opdivo (nivolumab) as a first line of treatment before starting therapy, according to a Phase 3 clinical trial. The results…
This post was originally published on this site Aquablation is a safe and more efficient procedure to treat men with symptoms of benign prostatic hyperplasia (BPH) than is TURP, according to early results of the Phase 3 WATER trial (NCT02505919). Preliminary trial safety and efficacy findings were presented at the recent American Urological Association (AUA) Annual Meeting in…
This post was originally published on this site Prostate Cancer UK has awarded more than $355,000 (£275,000) to University of Birmingham researchers to develop a diagnostic tool that can measure the aggressiveness of a patient’s prostate cancer. The new technology will help physicians identify the best course of treatment for each patient. The grant is part…
This post was originally published on this site Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, results of a Phase 3 trial show. The benefits were seen across multiple patient subgroups, regardless of initial…
This post was originally published on this site Scientists from the Queen Mary University of London have received grants worth more than £2.5 million ($3.2 million), awarded by Prostate Cancer UK to advance prostate cancer research. The funds, which are part of the charity’s Research Innovation Awards scheme, aim to foster innovative and ambitious research projects across the…
This post was originally published on this site The Prostate Cancer Foundation (PCF) has granted a $1 million Challenge Award to researchers from the Masonic Cancer Center at the University of Minnesota to support their investigations into new therapies for prostate cancer. With this award, the PCF hopes to accelerate the development of strategies to improve…
